Tenax Therapeutics (TENX) Other Non Operating Income (2010 - 2026)
Tenax Therapeutics recorded quarterly Other Non Operating Income of -$4000.0 in Q1 2026, up 55.56% quarter-over-quarter from -$9000.0 in Q4 2025.
Tenax Therapeutics' Other Non Operating Income history runs 16 years deep, the most recent figure standing at -$4000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income changed N/A year-over-year to -$4000.0; the TTM figure through Mar 2026 stood at -$37000.0 (down 1494.12% YoY), while the FY2025 annual figure was -$33000.0, down 3400.0% from the prior year.
- Other Non Operating Income came in at -$4000.0 for Q1 2026 at Tenax Therapeutics, up from -$9000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $125866.0 in Q4 2023 to a low of -$140055.0 in Q1 2023.
- A 5-year average of -$12442.9 and a median of -$3146.0 in 2022 frame the typical range for Other Non Operating Income.
- On a YoY basis, Other Non Operating Income climbed as much as 2261.53% in 2023 and fell as far as 45279.03% in 2023.
- Tenax Therapeutics' Other Non Operating Income stood at -$5823.0 in 2022, then jumped by 2261.53% to $125866.0 in 2023, then sank by 98.69% to $1654.0 in 2024, then slumped by 644.14% to -$9000.0 in 2025, then jumped by 55.56% to -$4000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$4000.0, -$9000.0, and -$15000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,000.00 |
| Dec 31, 2025 | -9,000.00 |
| Sep 30, 2025 | -15,000.00 |
| Jun 30, 2025 | -9,000.00 |
| Dec 31, 2024 | 1,654.00 |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | -117,449.00 |
| Dec 31, 2023 | 125,866.00 |
| Jun 30, 2023 | 911.00 |
| Mar 31, 2023 | -140,055.00 |
| Dec 31, 2022 | -5,823.00 |
| Sep 30, 2022 | -1,323.00 |
| Jun 30, 2022 | -2,292.00 |
| Mar 31, 2022 | 310.00 |
| Dec 31, 2021 | 1,235.00 |
| Sep 30, 2021 | 3,642.00 |
| Jun 30, 2021 | -247,820.00 |
| Mar 31, 2021 | -2,135.00 |
| Dec 31, 2020 | 32,204.00 |
| Sep 30, 2020 | -5,298.00 |
| Jun 30, 2020 | 2,101.00 |
| Mar 31, 2020 | -10,841.00 |
| Dec 31, 2019 | 300,062.00 |
| Sep 30, 2019 | -36,709.00 |
| Jun 30, 2019 | -58,122.00 |
| Mar 31, 2019 | -44,331.00 |
| Dec 31, 2018 | 149,458.00 |
| Sep 30, 2018 | -18,224.00 |
| Jun 30, 2018 | -21,311.00 |
| Mar 31, 2018 | -30,087.00 |
| Dec 31, 2017 | 693,941.00 |
| Sep 30, 2017 | -76,226.00 |
| Jun 30, 2017 | -28,199.00 |
| Mar 31, 2017 | -223,301.00 |
| Dec 31, 2016 | 1.37 Mn |
| Sep 30, 2016 | -226,914.00 |
| Jun 30, 2016 | -30,027.00 |
| Mar 31, 2016 | 343,668.00 |
| Dec 31, 2015 | 359,041.00 |
| Sep 30, 2015 | 183,605.00 |
| Jun 30, 2015 | 120,482.00 |
| Apr 30, 2013 | 3,468.00 |
| Jan 31, 2013 | 323.00 |
| Oct 31, 2012 | -6,911.00 |
| Jul 31, 2012 | 14,803.00 |
| Apr 30, 2012 | 11,811.00 |
| Jan 31, 2012 | -82,850.00 |
| Oct 31, 2011 | -3,927.00 |
| Jul 31, 2011 | -5,433.00 |
| Apr 30, 2011 | 285,952.00 |
| Jul 31, 2010 | -22,107.00 |